Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18th 2019

Lenvatinib in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate.

Dr. Zsiros Discusses Pembrolizumab Triplet in Recurrent Ovarian Cancer

March 18th 2019

Emese Zsiros, MD, PhD, discusses the results of her recent phase II trial that set out to evaluate the use of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Sentinel Lymph Node Excision Has Value in Endometrial Cancer

March 15th 2019

Although the therapeutic utility of lymphadenectomy is uncertain, it continues to provide information for staging and helps to guide postoperative adjuvant treatment for patients with endometrial cancer.

New Strategies and Novel Agents Transform Ovarian Cancer Into a Chronic Condition

March 7th 2019

The immediate future of clinical investigation in ovarian cancer is remarkably exciting, with a number of novel agents and combination strategies currently being examined in multiple clinical trials.

Dr. Campos Discusses Differences Between PARP Inhibitors in Recurrent Ovarian Cancer

March 5th 2019

Susana Campos, MD, MPH, assistant professor of medicine, Harvard Medical School, and Dana-Farber Cancer Institute, discusses differences between PARP inhibitors in recurrent ovarian cancer.

Dr. Ganjoo on the Treatment of Metastatic Uterine Leiomyosarcoma

February 21st 2019

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with metastatic uterine leiomyosarcoma.

Dr. George Discusses Ongoing Trials in Soft Tissue Sarcoma

February 12th 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of Medicine, Harvard Medical School, discusses ongoing trials in soft tissue sarcoma (STS).

New Agents Push the Envelope in Ovarian Cancer

February 10th 2019

Although there have been numerous studies evaluating the role of different therapy schedules, cytotoxic agents, and routes of administration in ovarian cancer, the backbone of therapy remains a combination of a platinum and a taxane.

Dr. Karam on the Use of Laparoscopy in Advanced Ovarian Cancer

February 9th 2019

Amer Karam, MD, associate clinical professor of Gynecologic Oncology at Stanford Hospital and director of Robotic Surgery and Outreach in the Division of Gynecologic Oncology at Stanford Medicine, discusses the use of laparoscopy in advanced ovarian cancer.

Expert Focuses on Facets of Genetic Testing in Ovarian Cancer

January 31st 2019

Huma Q. Rana, MD, discusses the evolution of genetic testing in ovarian cancer and the genes that are associated with an increased risk of subsequent cancer development.

Matulonis Highlights Novel Strategies, Emerging Agents in Ovarian Cancer

January 25th 2019

Ursula A. Matulonis, MD, highlights available and emerging treatment options and strategies for patients with recurrent ovarian cancer.

Dr. English on an Investigational Antibody-Drug Conjugate in Ovarian Cancer

January 25th 2019

Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses an investigational antibody-drug conjugate (ADC) in ovarian cancer.

FDA Places Partial Hold on Cervical Cancer Trial of AIM2CERV

January 24th 2019

The FDA has placed a partial clinical hold on the phase III AIM2CERV trial evaluating the use of axalimogene filolisbac in patients with high-risk locally advanced cervical cancer.

Patient Selection Key to Future of Immunotherapy in Endometrioid Disease

January 22nd 2019

Successful application of immunotherapy in endometrial cancer means identifying the patients with inflamed tumors who will respond to treatment and those who will not, and finding ways to treat noninflamed tumors with immunotherapy agents.

Ongoing Research to Move Needle Forward in Gynecologic Cancer Treatment

January 21st 2019

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

Dr. Leath Discusses Unmet Need in Cervical Cancer

January 20th 2019

Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.

Westin Highlights the Evolving Role of PARP Inhibitors in Ovarian Cancer

January 19th 2019

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

Dr. Suarez Mora On Sequential Sampling of IP Fluid During Chemotherapy

January 19th 2019

Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.

Dr. Essel on Quantitative Computed Tomography Image Feature Analysis in Gynecologic Cancers

January 19th 2019

Kathleen G. Essel, MD, gynecologic oncology fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancer

January 19th 2019

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.